About us Services Careers Contact us Privacy Coripharma launches Eslicarbazepine through a strong partner in Europe 01. Jul 2021 Coripharma is launching its first developed product, Eslicarbazepine 200mg & 800mg tablets, through a strong European partner. Eslicarbazepine is an anticonvulsant medication used for epilepsy and is the first product launched out of Coripharma´s growing development pipeline. Coripharma has applied for further marketing authorisations for this product and will, through multiple partnership agreements, be launching Eslicarbazepine in different European countries throughout the year. Jonina Gudmundsdottir, CEO Coripharma: “The successful launch of our first developed product is an important milestone in Coripharma’s history and signals the strength and experience of our team. This patent expiry launch is in line with our earlier communicated plans and will further boost our confidence as we continue the growth plan of future pipeline launches”. When you browse on this site, cookies collect data to enhance your experience. Visit our privacy policy (updated 15 APR 2019) and consent tool to learn more, and make choices about the data used. By clicking "Accept" or by continuing to use the site, you agree to this use of cookies and data. Privacy policy Consent tool Accept About us Services Careers Contact us Privacy Coripharma Reykjavikurvegur 78 - 80 220 Hafnarfjordur, Iceland Email info@coripharma.is Phone +354 4206700